Notification: The cat. code has been changed from bimab-hcd19bgal to bimab-cd19bg-01.

Anti-hCD19-βGal binds to hCD19 on B cells but not to hCD3 on T cells

Monoclonal scFv antibody against human CD19 and β-galactosidase; Negative control

Anti-hCD19-βGal is a bispecific antibody that binds to two sites: hCD19 expressed on the surface of B cells, and E. coli β-galactosidase (β-Gal). It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, like Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].

References:

1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.

Clear allRefined by

Products1

1 Search results: BIMAB-CD19BG-01